The interactions between bone marrow (BM) microenvironment and acute myeloid leukemia (AML) is known to promote survival of AML cells. In this study, we used reverse phase-protein array (RPPA) technology to measure changes in multiple proteins induced by stroma in leukemic cells. We then investigated the potential of an mTOR kinase inhibitor, PP242, to disrupt leukemia/stroma interactions, and examined the effects of PP242 in vivo using a mouse model.
Introduction
Functional interplay between acute myeloid leukemia (AML) cells and the bone marrow (BM) microenvironment is a distinct feature of this hematological malignancy. Several studies have provided evidence suggesting that proliferation, survival, and drug resistance of AML can be modulated by mesenchymal stem cells (MSCs) within the BM microenvironment [1] [2] [3] [4] . Direct contact between AML cells and BM-derived MSCs triggers a pleiotropic spectrum of proliferative and/or antiapoptotic signaling pathways, including the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) 5;6 pathway (PI3K/AKT/mTOR), which attenuates the response of AML to conventional chemotherapy.
Thus, in addition to therapies that directly target AML, interruption of leukemia cell-MSC interactions should be considered when designing anti-AML therapeutic strategies.
mTOR is a critical component of PI3K/AKT signaling, forming two complexesmTORC1 and mTORC2-that are defined by their molecular composition and substrate specificity. mTORC1 includes mTOR and raptor 7 , whose downstream targets are the eukaryotic translation initiation factor 4E-binding proteins (4EBPs) and S6 kinases (S6K1 and S6K2).
4EBP1 phosphorylation by mTORC1 releases 4EBP1 from eukaryotic translation initiation factor 4E (eIF4E), allowing eIF4E to form the eIF4F complex that promotes cap-dependent mRNA translation. Phosphorylation of S6Ks by mTORC1 is an activating event that potentiates S6K-dependent phosphorylation of ribosomal S6 protein and other substrates that coordinate aspects of protein and lipid biosynthesis while opposing autophagy 8 . In comparison, mTORC2
contains mTOR and rictor 9 . It phosphorylates AKT at Ser473 and members of the AGC protein kinase family at hydrophobic motifs. These include protein kinase C isoforms and members of the glucocorticoid-induced kinase family 10 .
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Rapamycin and its derivatives (RAD001 and CCI-779) are first generation mTOR inhibitors which showed only modest efficacy in anti-tumor clinical trials 11 . These compounds affect mTORC1 more than mTORC2, especially in the initial phase of treatment, resulting in increased AKT phosphorylation through blocking negative feedback loops that limit upstream signaling by PI3K 11;12 . In addition, these agents do not completely inhibit mTORC1 activity and have little effect on phosphorylation of 4EBP1 at key threonine residues (Thr37/46), resulting in weak attenuation of cap-dependent translation and little effect on overall protein synthesis 13 .
PP242 is a new small-molecule protein kinase inhibitor that targets the ATP-binding site of mTOR, resulting in greater inhibition of mTORC1 and mTORC2 activity than that produced by the mTOR inhibitors discussed above 14 . Compared to the other PI3K/mTOR inhibitors, such as PI-103, PP242 is more selective for leukemic cells, as evidenced by its ability to suppress PI3K/AKT/mTOR signaling in Ph + B-cell acute lymphoblastic leukemia 15;16 and T-cell lymphoma cells 17 , and prolongation the survival of mice harboring these leukemias.
Microenvironment-mediated chemoresistance of AML prompted us to investigate signaling pathways activated in leukemic cells upon contact with stromal cells, and to study the anti-leukemia potency of mTOR kinase inhibitors under conditions mimicking the BM microenvironment. In this study, we report that stroma activates multiple antiapoptotic signaling through several protein-protein interactions that correlate with stroma-mediated survival in AML cells. We further show that the PP242 effectively inhibits the activity of mTORC1 and mTORC2
and their downstream targets in primary AML cells, inducing apoptosis in both primary AML blasts and CD34+ progenitor cells. Importantly, PP242 disrupts the stroma-leukemia interaction,
antagonizing stroma-mediated survival by suppressing expression of CXC chemokine receptor type 4 (CXCR4) and downregulating mTOR signaling, both in primary AML cells and in 
Materials and Methods

Cells and culture conditions
Peripheral blood and bone marrow samples were obtained from patients with AML or ALL after informed consent was obtained in accordance with The University of Texas MD Anderson Cancer Center Institutional Review Board regulations. Mononuclear cells were separated using Ficoll-Hypaque density gradient centrifugation (Sigma-Aldrich). Primary cells were cultured in RPMI 1640 containing 10% fetal bovine serum (FBS), 1% L-glutamine, and 1% penicillinstreptomycin. Mesenchymal stem cells (MSCs) obtained from healthy BM donors or from patients with leukemia were cultured at a density of 5,000 to 6,000 cells/cm 2 in minimum essential medium (MEM) alpha supplemented with 20% FBS, 1% L-glutamine, and 1% penicillin-streptomycin as described elsewhere 18 . The isolated, cultured MSCs at passage 3 comprised a single phenotypic population, as determined by flow cytometric analysis, positive for SH2 and SH3 and negative for markers of hematopoietic lineage, as described elsewhere 19 .
Passage 3 or 4 MSCs were used for co-culture experiments. The murine stromal cell line MS-5 was provided by Dr. Itoh 20 from Niigata University (Japan) and maintained in the 10% FBS-containing MEMα.
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Cell viability
Cell viability was measured using flow cytometry with CountBright absolute counting beads (Invitrogen). The percentage of apoptosis was estimated by measuring phosphatidylserine externalization in the cells using annexin V flow cytometry (Roche). Apoptosis of bulk leukemic and leukemic progenitor cells was measured using annexin V+ after electronic gating on CD45+ leukemic blasts (CD45-APC; BD Pharmingen) or CD34+ (CD34-APC; BD Pharmingen) AML progenitor cells. The extent of apoptosis was quantified as percentage of annexin V-positive cells, and the extent of drug-specific apoptosis was assessed by the formula: % specific apoptosis = (test -control) x 100 x / (100 -control). "Control" represent the percentage of annexin V positivity in the group of cells without treatment (spontaneous apoptosis), and "Test" represents the percentage of annexin V positivity in the group of cells treated with PP242.
Flow cytometry for detection of the expression level of proteins and intracellular phosphoproteins
Murine whole blood (100 μL), harvested primary AML cells, and harvested AML MSCs were fixed with formaldehyde at a final concentration of 4% for 10 minutes at room temperature, permeabilized with 0.1% Triton X-100 at 37°C for 15 minutes, and then centrifuged at 1000g (Beckman Coulter) in cold 50% methanol for 3 minutes. The pellets were washed twice in icecold phosphate-buffered saline (PBS). Cells were then stained for cell surface markers and intracellular signaling markers at room temperature for 30 minutes and washed once with PBS before analysis using a Gallios flow cytometer (Beckman Coulter). The flow cytometric profiles were analyzed using the Kaluza (Beckman Coulter) or FlowJo (version 7.6.1) software programs. The antibodies against cell surface markers CD34-Cy5 and CD90-APCAlexa750 were purchased from Beckman Coulter. The antibodies against CXCR4-phycoerythrin (PE; 12G5), 
Leukemia mouse model
All animal experiments were performed in accordance with protocols approved by the MD Anderson Institutional Animal Care and Use Committee. To evaluate the inhibitory effect of PP242 on mTOR in vivo, a mouse model of leukemia was generated using severe combined immunodeficient (SCID) mice. The mice were irradiated at 6 Gy and 6 hours later injected intravenously with Baf/ITD/luc/GFP cells (kindly provided by Dr. D. Small, John Hopkins) 21;22 at a concentration of 0.2 × 10 6 cells/mouse. To compare the effects of PP242 and rapamycin (Sigma-Aldrich), one group of mice (nine mice per group) was injected with rapamycin intraperitoneally at a dose of 0.5 mg/kg every other day. Mice in the other group were given PP242 (60 mg/kg, via gavage, every other day) was initiated on day 3 after the tumor cells injection. Tumor-cell engraftment and progression were then monitored using noninvasive
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From imaging as described previously 23 , and flow cytometry to detect the GFP+ leukemia cells in murine peripheral blood samples. To assess the inhibitory effect of PP242 on mTOR signaling in GFP+ cells, murine peripheral blood was collected before and 2 hours after PP242 administration. Effects on mTOR signaling components p4EBP1(Thr37/43), pAKT (Ser473), and pS6K (Ser243/244) were analyzed using flow cytometry. Anti-tumor effects were compared using bioluminescent imaging.
Western blot analysis
For Western blot analysis of the inhibitory effects of PP242 on mTOR, primary AML samples were lysed in a phosphoprotein lysis buffer (150 mM NaCl, 1 mM 
Reverse-phase protein array
Two AML cell lines (OCI-AML3 and U937) and 20 blood samples obtained from patients with primary AML (19) or ALL(1) with more than 50% blasts were cultured alone or co-cultured with mouse stromal MS-5 cells for 24 hours. Cells were lysed in a protein lysis buffer (2×; 0.5 M Tris-HCl, pH 6.8, 2% sodium dodecyl sulfate, 10% glycerol, 4% β-mercaptoethanol), then heated at 95°C for 5 minutes and stored at -80°C. To verify lack of significant contamination in collected leukemic cells, anti-human CD45-APC and CD34-APC were measured by flow cytometry to discriminate between human leukemic cells and mouse stroma cells (MS5).
Proteomic profiling of the samples was performed using reverse-phase protein arrays (RPPA). The resulting comprehensive profiles included measures of 51 proteins (Supplementary table 1) representing the level of activation and expression of proteins in signal transduction pathways and apoptosis networks in response to different culture conditions. The methods for using and validating RPPAs were fully described previously 24 . Briefly, protein lysates obtained from primary samples were printed onto slides, together with normalization and expression controls, in five serial dilutions. The slides were probed with strictly validated primary antibodies against total or phosphorylated protein (as described in the supplementary section) and a secondary antibody was used to amplify the signal. The stained slides were scanned using a scanner and the images were analyzed using the MicroVigene software program (VigeneTech, Carlisle, MA) to produce quantified data.
The "Supercurve" algorithm 25 was used to estimate the sample-specific protein expression levels. The RPPA data were normalized by median centering the results for each sample across all antibodies. The expression levels of proteins were examined under two different culture settings (with or without MS5), and the effect of culture setting changes in each 
Quantitative real-time PCR
Total RNA was extracted using Trizol (Invitrogen, Grand Island, NY) as directed by the manufacturer; cDNA was then prepared using SuperScript III primed by random hexamers as described by Andreeff et al. (2008) . 27 The level of expression of CXCR4 was assessed by real time PCR using the following TaqMan (Table   1) . Specifically, it upregulated pAKT (Thr308), phosphorylated extracellular signal-regulated pERK (Thr202/204), and pSTAT3 (Thr727), and downregulated pβ-catenin (Ser33/37/Thr41) expression.
Furthermore, six proteins were altered in the majority of the samples when co-cultured with stroma. Co-culture with stroma upregulated pAKT (Thr308) , in 13 samples (Table 1 ). These findings indicate that stroma triggers activation of multiple parallel pro-survival signaling pathways in leukemic cells.
PP242 overcomes protection by stroma and induces apoptosis in primary AML cells
Since activation of pAKT (Thr308) and upregulation of mTOR were seen in primary AML cells co-cultured with stroma, we wanted to assess the anti-leukemic efficacy of PP242 under stromal co-culture conditions. To this end, we cultured cells from 9 AML samples (Supplementary Table   2 
PP242 impairs interactions between primary AML cells and AML MSCs through inhibition of mTOR signaling in both cell types
Several studies have demonstrated that leukemia cells reside in close contact with stromal cells in BM microenvironments and that direct cell-cell contact plays an important role in the activation of intracellular signaling. One of the challenges in studying leukemia-stroma interactions is identifying and separating the different cell types in co-culture. To avoid physical cell separation while assessing the rapid signaling events upon direct leukemia-stroma cell-cell contact, we utilized phospho-specific multiparameter flow cytometry. To this end, we isolated primary BM MSC from 11 AML samples and one normal healthy donor. Using a co-culture (Fig. 3A dashed line) , and activated pS6K (Ser235/236) in majority of AML (P = .03; n = 15, dashed line) and CD34+ progenitor cells attached to stroma in 14 of 16 samples (P = .04; n = 14) (Fig. 3B dashed line) . Treatment with PP242 effectively suppressed the phosphorylation of 4EBP1 (Thr37/46) (P < .001; n = 16), AKT (Ser473) (P = .02; n = 12), and S6K (Ser235/236) (P = .05; n = 15) in floating leukemia cells, and downregulated the phosphorylation of AKT (Ser473) in majority of floating CD34+ AML progenitor cells (P = .05, n = 12). Importantly, PP242 exerted its inhibitory effect on p4EBP1 (Thr37/46) and pAKT (Ser473) in both attached AML cells (P = .03, n = 16; P = .01, n = 12, respectively) and most of attached CD34+ AML progenitor cells (P = .02; n = 16; P = .02; n = 12, respectively) and Table 2 . Treatment with PP242 reduced the expression of CXCR4 in the majority of AMLs, AML CD34+ cells and MSCs, cultured alone or co-cultured ( Fig. 5Ab and Supplementary Fig. 4 Figure 5C ). On the contrary, PP242 minimally affected VLA4 and CD44 expression, suggesting specificity of changes in CXCR4 levels. However, PP242 at 30 and 60 min had no effect on CXCR4 expression, while it inhibited both mTORC1/C2 functions via inactivating the phosphorylation of S6K by 70%, and of AKT (Ser 473) by 50% (Supplementary Figure 6C) . To evaluate the possibility of PP242 affecting internalization of surface CXCR4, we measured CXCR4 levels using 12G5 and 1D9 antibodies in live (surface) vs. fixed/permeabilized (intracellular) cells and found comparable decrease, arguing for changes in total protein levels rather than redistribution phenomenon (Supplementary Figure   8A , B). Twenty-four hour exposure to temsirolimus did not affect cell viability and caused modest decrease of cell surface and intracellular CXCR4 levels (Supplementary Figure 7A, B) .
Taken together, these results indicate that PP242 selectively decreases CXCR4 expression following blockade of the intracellular mTOR signaling. Importantly, this effect is seen in primary AML cells and MSCs, cultured alone or co-cultured.
PP242 reduces leukemia burden and extends survival in a mouse model of leukemia
We further evaluated the anti-leukemic potential of PP242 in vivo using a mouse model of leukemia generated by Baf3/ITD-GFP/luc in NOD/Scid mice 21;22;31 . We monitored leukemia burden in murine peripheral blood using flow cytometry gated on GFP+ circulating cells. As shown in Figure 6A , 2 hours after PP242 administration, PP242 inactivated the mTORC1 downstream targets p4EBP1 (Thr37/46) and pS6K (Ser235/236) and mTORC2 direct target pAKT (Ser473) in circulating FLT3-ITD-GFP leukemic cells. PP242 at 60 mg/kg reduced leukemia burden as measured by bioluminescence imaging ( Figure 6B a-b) . The anti-leukemia effect of PP242 was greater than that of rapamycin used at 0.5 mg/kg, the tolerable dose that was previously shown to inhibit mTOR signaling 15 .
Discussion
The interaction of AML cells with stroma within the BM microenvironment attenuates the response of AML cells to conventional chemotherapeutic agents and promotes chemoresistance. Furthermore, PP242 is more effective in preventing the occurrence of negative feedback loops by enhancing its inhibitory effect on mTORC2 11;12 . Consequently, PP242 is a more potent inhibitor of protein synthesis, metabolism, and proliferation of cancer cells. In this study, PP242 exhibited 
